Acute lymphocytic leukemia.
Chronic myelogenous leukemia, Kaposi sarcoma.
Other dose regimens are used. In adults, cumulative dose should not exceed 550 mg/m² (450 mg/m² if previous chest radiation)
Forms a complex with DNA, which subsequently inhibits DNA and RNA synthesis (cell-cycle phase-nonspecific).
Death of rapidly replicating cells, particularly malignant ones. Also has immunosuppressive properties.
CV: Delayed dose-related cardiomyopathy; acute arrhythmias.
DERM: Alopecia; rash; contact dermatitis; urticaria; radiation recall; nail hyperpigmentation.
GI: Nausea; vomiting; mucositis; esophagitis; diarrhea; abdominal pain.
HEMA: Bone marrow suppression.
OTHER: Fever; chills.
May result in increased daunorubicin toxicity.
May impair liver function and increase the risk of toxicity.
Dosage reduction of daunorubicin may be required.
Daunorubicin may decrease the oral absorption of quinolone antibiotics.
Therapeutic Classification: antineoplastics
Pharmacologic Classification: anthracyclines
Absorption: Administered IV only, resulting in complete bioavailability.
Distribution: Widely distributed. Crosses the placenta.
Metabolism/Excretion: Extensively metabolized by the liver. Converted partially to a compound that also has antineoplastic activity (daunorubicinol); 40% eliminated by biliary excretion.
Half-life: Daunorubicin — 18.5 hr. Daunorubicinol — 26.7 hr.
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal